secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dare Bioscience, Inc. (DARE)
CIK:        0001401914
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001493152-24-019087
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Daré Bioscience Q1 cash $3.6M, secures $22M royalty financing; Ovaprene Phase 3 ongoing
--------------------------------------------------------------------------------

- Cash & equivalents $3.6M at March 31, 2024; subsequent $22M non-dilutive royalty financing from XOMA and $1M grant installment.
- R&D expenses $3.3M in Q1 2024, down 34% YoY from $5.0M; G&A $2.7M vs $3.3M.
- Ovaprene Phase 3 contraceptive study recruiting at 18 US sites; central ad campaign launched March 2024.
- Sildenafil Cream end-of-Phase 2 meeting with FDA completed; additional feedback expected 2Q2024 for Phase 3 design.
- XACIATO commercialized by Organon since Q4 2023; first FDA-approved product from Daré portfolio.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224019087/0001493152-24-019087-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401914/000149315224019087/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019087

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer